Autosomal recessive osteopetrosis and TCIRG1-related disorders
Research activity in pediatric hereditary bone disease includes autologous hematopoietic stem and progenitor cell approaches for osteopetrosis linked to TCIRG1 mutations, with attention to safety and clinical efficacy.
- TCIRG1-associated autosomal recessive osteopetrosis
- Ex vivo hematopoietic stem cell gene therapy
- Pediatric bone marrow and skeletal disease
The sponsor’s work in this area centers on genetic correction strategies for severe inherited skeletal disease affecting children.
Wiskott-Aldrich syndrome and immune deficiency
Clinical research covers Wiskott-Aldrich syndrome and WAS, with studies focused on autologous lentiviral hematopoietic stem cell gene therapy and follow-up of treated subjects, addressing bleeding, infection susceptibility, and immune dysfunction.
- Wiskott-Aldrich syndrome (WAS)
- Immune system repair
- Bleeding disorders and severe infections
The therapeutic interest extends to durable immune reconstitution in inherited primary immunodeficiency.
Transfusion-dependent beta-thalassemia
Another major area is hemoglobinopathy research in transfusion-dependent beta-thalassemia, with emphasis on gene therapy using autologous CD34+ hematopoietic stem cells and the goal of reducing or eliminating chronic transfusion needs.
- Transfusion-dependent beta-thalassemia
- Autologous CD34+ stem cell therapy
- Transfusion independence
This area reflects interest in inherited red blood cell disorders and curative genetic treatment options.
Hematopoietic stem cell gene therapy platforms
Across its studies, the sponsor is involved in lentiviral vector-based ex vivo hematopoietic stem cell therapies, including autologous cell products and cryopreserved formulations for inherited diseases.
- Lentiviral vector-mediated gene transfer
- Autologous ex vivo cell therapy
- Cryopreserved cellular products
These programs are concentrated in rare genetic disorders managed through cell-based molecular therapy.
